Gold Or Platinum Patents (Class 424/649)
  • Patent number: 10940215
    Abstract: The present disclosure relates to: an adipocyte-targeting non-viral gene delivery complex comprising a sh(FABP4+FABP5) dual plasmid vector; and treatment for obesity and obesity-induced metabolic syndromes by using the same and, more particularly, to a gene delivery complex comprising: an adipocyte-targeting sequence; a nine-arginine (R9) peptide; and a dual plasmid vector comprising a gene for treatment of obesity and obesity-induced metabolic syndromes, wherein the gene for treatment of obesity and obesity-induced metabolic syndromes is a base sequence inhibiting the expression of a FABP4 gene and a FABP5 gene. According to the present disclosure, in order to treat obesity-related diseases, a dual plasmid vector capable of simultaneously inhibiting the FABP4 and FABP5 genes is produced, and this vector is bound to a predetermined delivery system that specifically delivers the vector into adipocytes so as to provide a gene delivery complex.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: March 9, 2021
    Assignee: Industry-University Cooperation Foundation Hanyang University
    Inventors: Yong-Hee Kim, Hyung Jin Kim, Jee Young Chung, Yoon Sung Song
  • Patent number: 10898473
    Abstract: This application describes compounds, compositions, and combinations thereof that can be used to treat cancer, such as cancers with and without BRAF and/or KRAS mutations.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: January 26, 2021
    Assignee: EVOL SCIENCE LLC
    Inventors: Andrew J. Andrews, Vikram Bhattacharjee
  • Patent number: 10869879
    Abstract: This application describes compounds, compositions, and combinations thereof that can be used to treat cancer, such as cancers with and without BRAF and/or RAS mutations.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: December 22, 2020
    Assignee: EVOL SCIENCE LLC
    Inventor: Vikram Bhattacharjee
  • Patent number: 10857113
    Abstract: Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: December 8, 2020
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 10821114
    Abstract: The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: November 3, 2020
    Assignees: INSTITUT CURIE, HARMONIC PHARMA
    Inventors: Arnaud Sinan Karaboga, Violeta Isabel Perez-Nueno, Michel Souchet, Didier Decaudin
  • Patent number: 10821095
    Abstract: IT-139, sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 3, 2020
    Assignee: Bold Therapeutics, Inc.
    Inventors: Suzanne Bakewell, Jyothi Sethuraman
  • Patent number: 10772898
    Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: September 15, 2020
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Michael B. Yaffe, Jesse C. Patterson
  • Patent number: 10751296
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: August 25, 2020
    Assignee: CAVA HEALTHCARE INC.
    Inventors: Wilfred Jefferies, Reinhard Gabathuler, Raymond Andersen, Lilian Nohara, David Williams
  • Patent number: 10744171
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Sequential treatment with the virus construct followed by chemotherapy drugs increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioblastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: August 18, 2020
    Assignee: Duke University
    Inventors: Darell D. Bigner, Matthias Gromeier, Annick Desjardins, Henry S. Friedman, Allan H. Friedman, John H. Sampson
  • Patent number: 10632115
    Abstract: The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 28, 2020
    Assignee: Peking University Third Hospital
    Inventors: Chunli Song, Ning Yang, Yueyi Cui, Yingsheng Yu
  • Patent number: 10612093
    Abstract: The present invention relates to a method of selecting a target region of interest (ROI) in a target nucleic acid molecule using a nucleic acid probe comprising sequences capable of directing the cleavage of a target nucleic acid molecule to release a fragment comprising the ROI and sequences capable of templating the circularisation and ligation of the target fragment. The circularised molecule thus obtained contains the selected ROI and may be subjected to further analysis and/or amplification etc. Also provided are probes and kits for use in such methods.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: April 7, 2020
    Assignee: NAVINCI DIAGNOSTICS AB
    Inventors: Ulf Landegren, Rachel Yuan Nong
  • Patent number: 10595550
    Abstract: The present invention is directed to a therapeutic composition including an active therapeutic ingredient combined with a liquid or solution based carbonated beverage. The invention as described details the use or administration of the therapeutic composition so as to treat a variety of ailments. The present invention is also directed to a method of administering the therapeutic composition to an individual for the purposes of alleviating an ailment. In a further arrangement, the therapeutic composition is provided to a user as a pre-packaged volume containing a single effective dose of the therapeutic agent.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: March 24, 2020
    Assignee: VISION PHARMA, LLC
    Inventor: Sander S Busman
  • Patent number: 10576082
    Abstract: Use of an ErbB2 inhibitor for promoting ErbB2-regulated autophagic degradation or clearance of APP-C99 and APP intracellular domain (AICD) and/or alleviating production of Abeta 40 and Abeta 42 in a subject in need thereof is disclosed. Use of an ErbB2 inhibitor for rescuing ErbB2-mediated inhibition of autophagic flux in a subject in need thereof is also disclosed. Use of an ErbB2 inhibitor for enhancing spatial learning and memory, and/or for cognitive improvement, in a subject with ErbB2-associated Alzheimer's disease is further disclosed. Also disclosed is use of an ErbB2 inhibitor for reducing intracellular levels of C99 and AICD without affecting extracellular domain-truncated Notch and Notch intracellular domain in a subject in need thereof.
    Type: Grant
    Filed: September 3, 2017
    Date of Patent: March 3, 2020
    Assignee: ACADEMIA SINICA
    Inventors: Yung-Feng Liao, Bo-Jeng Wang
  • Patent number: 10485768
    Abstract: The present invention includes a composition and method for treating a glioblastoma in a human or animal subject comprising the steps of: identifying the human or animal subject in need of treatment of a glioblastoma, wherein the human or animal is no longer responsive to at least one of chemotherapy, surgery, or radiation therapy; and administering to the human or animal subject a therapeutically effective amount of a composition comprising: an amount of a curcumin or curcuminoids in one or more liposomes, or curcumin or curcuminoids and empty liposomes and administered prior to, concomitantly, or after administration of the curcumin or curcuminoids, that is effective for treating the glioblastoma, wherein the liposomal curcumin or curcuminoids, or empty liposomes, eliminate the QT prolongation caused by the curcumin or curcuminoids; and at least one chemotherapeutic agent that is synergistic with curcumin to treat the glioblastoma.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: November 26, 2019
    Assignee: Signpath Pharma, Inc.
    Inventors: Laura A. Sordillo, Peter P. Sordillo, Lawrence Helson
  • Patent number: 10386359
    Abstract: Disclosed are methods for determining whether a patient will achieve a response after radiation therapy, in particular a method for determining whether a patient suffering from a cancer will achieve a response after radiation therapy including the steps of i) determining the level of ceramide in a first blood sample obtained from the patient before radiation therapy, ii) determining the level of ceramide in a second blood sample obtained from the patient during or just after radiation therapy, iii) comparing the level determined at step i) with the level determined at step ii) and iv) concluding that the patient will achieve response when the level determined at step ii) is higher than the level determined at step i) or concluding that the patient will not achieve a response when the level determined at step ii) is lower than the level determined at step i).
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: August 20, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, UNIVERSITE D'ANGERS, CENTRE NATIONAL DE LA RECHERCHE SCIENTLFIQUE (CNRS), INSTITUT DE CANCERLOGIE DE L'OUEST—SITE RENE GAUDUCHEAU
    Inventors: Francois Paris, Nolwenn Dubois, Emmanuel Rio, Natacha Ripoche
  • Patent number: 10300026
    Abstract: Provided is a use of dihydroxyacetone in the preparation of a medicament, the medicament being used for treating a cancer.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: May 28, 2019
    Assignees: Shanxi Yabao Health Products Co., Ltd., Yabao Pharmaceutical Group Co., Ltd.
    Inventors: Jianguo Zhang, Wuxian Ren, Peng Wang, Bangqin Ya
  • Patent number: 10280178
    Abstract: Disclosed is a new compound that inhibits binding between a DX2 protein and a p14/ARF protein, a pharmaceutical composition including the new compound as an effective component for treating or preventing a cancer disease, an anticancer adjuvant for improving an anticancer effect of a drug-resistant anticancer drug, and a composition including an AIMP2-DX2 protein or a fragment thereof for diagnosing lung cancer.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: May 7, 2019
    Assignees: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
    Inventors: Bum Joon Park, Gyu Yong Song, Ah-Young Oh, Jee-Hyun Lee, Jin-Hyuk Her
  • Patent number: 10265294
    Abstract: The present invention provides the eutomeric isomer of the compound of formula (I), or a salt or solvate thereof, which can be used to treat epithelial cancer in a subject. In certain embodiments, the compound of formula (I) can be used in combination with AICAR and/or cisplatin.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: April 23, 2019
    Assignee: Yale University
    Inventors: Gil G. Mor, Ayesha Alvero
  • Patent number: 10251842
    Abstract: Nanocapsules of bioactive compounds derived from natural products as an adjunct treatment for cancer. Nanocapsules of bioactive compounds showed synergy in the treatment of cancer therapy-induced toxicity.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: April 9, 2019
    Assignee: King Abdulaziz University
    Inventors: Amna Ali Nasser Saddiq, Shaker Ahmad Mousa, Deena Shaker Mousa
  • Patent number: 10213449
    Abstract: Provided are methods and compositions for treating an individual who has a medulloblastoma. Methods for treating an individual who has a medulloblastoma tumor can include a step of administering to the individual, at a dose sufficient to reduce the size and/or growth rate of the medulloblastoma tumor, a composition that includes a casein kinase II (CK2) inhibitor (e.g., a CK2-selective inhibitor such as CX-4945). In some cases, the medulloblastoma tumor is a hedgehog-dependent medulloblastoma tumor. In some cases, the medulloblastoma tumor is a hedgehog-independent medulloblastoma tumor. In some cases, the medulloblastoma tumor is smoothened inhibitor-resistant (SMO inhibitor-resistant). In some cases, the medulloblastoma is resistant to treatment with 4,5,6,7-tetrabromo-2H-benzotriazole (TBB). In some cases, the dose is sufficient to cause long term regression of the medulloblastoma tumor, and in some cases, the dose is sufficient to increase the chance of survival of the individual.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: February 26, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Teresa Purzner, Matthew Peter Scott
  • Patent number: 10155006
    Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: December 18, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Michael B. Yaffe, Jesse C. Patterson
  • Patent number: 10145824
    Abstract: An improved analytical method for analysis of dianhydrogalactitol preparations provides a method for determining the purity of dianhydrogalactitol and detecting impurities in preparations of dianhydrogalactitol, as well as identifying any such impurities. The method employs high performance liquid chromatography (HPLC), in particular, HPLC with refractive index (RI) detection; the HPLC can be followed by tandem mass spectroscopy. The method can further comprise the step of performing preparative HPLC collection of at least one specific substance peak present in a preparation of dianhydrogalactitol.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: December 4, 2018
    Assignee: Del Mar Pharmaceuticals (BC) Ltd.
    Inventor: Xiaoyun Liu
  • Patent number: 10072021
    Abstract: Disclosed is a new compound that inhibits binding between a DX2 protein and a p14/ARF protein, a pharmaceutical composition including the new compound as an effective component for treating or preventing a cancer disease, an anticancer adjuvant for improving an anticancer effect of a drug-resistant anticancer drug, and a composition including an AIMP2-DX2 protein or a fragment thereof for diagnosing lung cancer.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: September 11, 2018
    Assignees: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)
    Inventors: Bum Joon Park, Gyu Yong Song, Ah-Young Oh, Jee-Hyun Lee, Jin-Hyuk Her
  • Patent number: 10066003
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: September 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10052304
    Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with ascorbate or a pharmaceutically acceptable salt thereof, at least one chelating agent that enhances ascorbate redox cycling (EDTA) to form H2O2, and one or more anti-cancer therapies.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: August 21, 2018
    Assignee: University of Iowa Research Foundation
    Inventors: Bryan G. Allen, Douglas R. Spitz, Garry R. Buettner, Joseph Cullen, Joshua Schoenfeld, Michael Schultz, Fenghuang Zhan
  • Patent number: 9994843
    Abstract: The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: June 12, 2018
    Assignee: National University Corporation Tokyo Medical and Dental University
    Inventors: Johji Inazawa, Jun Inoue, Shinsuke Yamamoto, Tatsuyuki Kawano, Ken-ichi Kozaki
  • Patent number: 9963452
    Abstract: The present invention relates to a method using some novel compounds and compositions for the inhibition of ROS tyrosine kinase. In particular, the present invention covers a method to treat abnormal cell growth, such as cancer, with ROS 10 inhibitors and compositions having ROS inhibitors. An illustrative compound of the invention is shown below Formula (I).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 8, 2018
    Assignee: AUGUSTA PHARMACEUTICALS INC.
    Inventors: Dorre A. Grueneberg, Ori Kalid, Jun Xian, Sharanappa B. Rajur, Hwa-Ok Kim, Venugopal Rao Neelagiri, Paresh Salgaonkar, Divakaramenon Sethumadhavan, Chaeho Moon, Madhavi Neelagiri
  • Patent number: 9950025
    Abstract: The present invention is concerned with immunostimulant compositions, in particular compositions comprising microparticulate form of muramyl dipeptide, and their use in the treatment of neoplastic disease.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: April 24, 2018
    Assignee: Innate Immunotherapeutics Limited
    Inventors: Frank B. Gelder, Gillian Alison Webster
  • Patent number: 9895366
    Abstract: The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: February 20, 2018
    Assignee: Peking University Third Hospital
    Inventors: Chunli Song, Ning Yang, Yueyi Cui, Yingsheng Xu
  • Patent number: 9884086
    Abstract: Disclosed is a method for providing information used for comparing restoration rates of damaged DNA, wherein information about a time period when Ataxia telangiectasia and Rad3 related (‘ATR’) activation is accelerated, on the basis of alternative information about an expression level of cryptochrome may be acquired, therefore, it can be determined that a restoration rate of damaged DNA is high at a time period when the expression level of cryptochrome is high. Accordingly, a time period when a restoration rate of DNA damaged by different causes is high, can be determined. Further, it is possible to estimate a time period when side effects occurring due to using an anticancer drug are minimized, and then, utilize the estimated result in determining the timing of administration of an anticancer drug.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: February 6, 2018
    Assignee: DONG-A UNIVERSITY RESEARCH FOUNDATION FOR INDUSTRY—ACADEMY COOPERATION
    Inventors: Tae Hong Kang, Jeong Min Park, Ji Ye Choi, Sun Hee Leem
  • Patent number: 9821008
    Abstract: Compositions and methods for inhibiting the DNA repair protein complex, ERCC1-XPF, and methods to enhance clinical responses to anticancer drugs that interact with DNA such as cisplatin, and to overcome drug resistance due to DNA repair mechanisms, are described.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: November 21, 2017
    Assignee: The University of Toledo
    Inventors: Stephan M. Patrick, Paul W. Erhardt, Christopher Trabbic
  • Patent number: 9809550
    Abstract: The invention provides quinolyl-hydrazones of Formula I, or pharmaceutically acceptable salts, esters, solvates, isomers and prodrugs thereof as well as pharmaceutical compositions containing these compounds for use in the prophylactic and/or therapeutic treatment of tuberculosis and related diseases, such as, diseases caused by nontuberculous mycobacteria and/or caused by Micobacterium leprae.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: November 7, 2017
    Assignee: TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.
    Inventors: Ana Lucia Almeida Ferreira, Ana Sofia Lopes, Augusto Eugenio Pardal Filipe, Pedro Filipe Eufrasio Pedroso, Susana Marques De Almeida Pecorelli, Carlos Caixado
  • Patent number: 9781924
    Abstract: A synthetic polymer film includes a surface which has a plurality of first raised portions, wherein a two-dimensional size of the plurality of first raised portions is in a range of more than 20 nm and less than 500 nm when viewed in a normal direction of the synthetic polymer film; and the surface has a microbicidal effect.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: October 10, 2017
    Assignee: SHARP KABUSHIKI KAISHA
    Inventors: Miho Yamada, Kiyoshi Minoura, Takahiro Nakahara, Seiji Takami
  • Patent number: 9770462
    Abstract: A method of treating ovarian, tubal and peritoneal cancer is revealed. It comprises administering an effective amount of a pharmaceutical composition (including a copper chelator, a platinum-based chemotherapeutic agent and an anthracycline) to a subject in need thereof for reducing concentration of intracellular copper ions and promoting activation of transcription factor Sp1 and human copper transporter 1 (hCTR1).
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: September 26, 2017
    Assignees: National Cheng Kung University, National Cheng Kung University Hospital
    Inventors: Cheng-Yang Chou, Tien-En Kuo, Yu-Fang Huang
  • Patent number: 9759698
    Abstract: An improved analytical method for analysis of dianhydrogalactitol preparations provides a method for determining the purity of dianhydrogalactitol and detecting impurities in preparations of dianhydrogalactitol, as well as identifying any such impurities. The method employs high performance liquid chromatography (HPLC), in particular, HPLC with evaporative light scattering detection (ELSD); the HPLC can be followed by tandem mass spectroscopy. The method can further comprise the step of performing preparative HPLC collection of at least one specific substance peak present in a preparation of dianhydrogalactitol.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: September 12, 2017
    Assignee: Del Mar Pharmaceuticals
    Inventor: Xiaoyun Liu
  • Patent number: 9663484
    Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: May 30, 2017
    Assignee: MEI PHARMA, INC.
    Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
  • Patent number: 9649305
    Abstract: A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one, is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as well as inhibiting glycolytic flux and PFKFB3 enzymatic activity in cells.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 16, 2017
    Assignee: Advanced Cancer Therapeutics, LLC
    Inventors: Gilles H. Tapolsky, Pooran Chand
  • Patent number: 9630956
    Abstract: The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: April 25, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Hayley Marie Binch, Dennis James Hurley, Thomas Cleveland, Pramod Joshi, Lev Tyler Dewey Fanning, Joanne Pinder, Michael O'Donnell, Anisa Nizarali Virani, Ronald Marcellus Alphonsus Knegtel, Steven John Durrant, Stephen Clinton Young, Pierre-Henri Storck, David Kay, Philip Michael Reaper, Matthew Paul Grote
  • Patent number: 9623074
    Abstract: The invention provides a method for promoting wound healing or tissue injury treatment in a subject in need thereof, the method comprising administering to the subject an effective amount of one or more fungal immunomodulatory protein (preferably, Ganoderma immunomodulatory protein).
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 18, 2017
    Assignee: 3D GLOBAL BIOTECH INC.
    Inventors: Keng-Liang Ou, Jungshan Chang
  • Patent number: 9593139
    Abstract: Compositions, kits, and methods for treatment of cancers are generally provided. In some embodiments, the compositions, kits, and methods comprise a platinum (e.g., Pt(II) or Pt(IV)) compound associated with a ligand (e.g., a beta-diketonate ligand) comprising a targeting moiety. Methods of synthesizing platinum (e.g., Pt(II) or Pt(IV)) compounds associated with a ligand comprising a targeting moiety are also provided.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: March 14, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Stephen J. Lippard, Justin J. Wilson, Robert John Radford, Maria R. Chan, Daniel Y. Zhang
  • Patent number: 9566280
    Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: February 14, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Michael B. Yaffe, Jesse C. Patterson
  • Patent number: 9492418
    Abstract: Compounds used to inhibit glycolytic pathway small molecule kinase 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase (PFKFB) are set forth; these inhibitors can be used in the treatment of certain diseases in which cells or tumors rely on glycolytic metabolism, such as many cancer cells.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: November 15, 2016
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Yong-Hwan Lee, Jeong Do Kim
  • Patent number: 9458457
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 4, 2016
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Patent number: 9415061
    Abstract: The present invention is concerned with immunostimulant compositions, in particular compositions comprising microparticulate form of murmyl dipeptide, and their use in the treatment of neoplastic disease.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: August 16, 2016
    Assignee: Innate Immunotherapeutics Limited
    Inventors: Frank B Gelder, Gillian Alison Webster
  • Patent number: 9402847
    Abstract: The present invention relates to a combination comprising (5)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof, hereafter “Compound (I)”, and a taxane. Taxanes include established cancer drugs such as docetaxel (Taxotere™) and paclitaxel (Taxol™). Such combinations may be useful in the treatment or prophylaxis of cancer. The invention also relates to a pharmaceutical composition comprising such Compound (I) and a taxane. The invention further relates to a method of treatment comprising the simultaneous, sequential or separate administration of Compound (I) and a taxane, to warm-blooded animal, such as man. The invention also relates to a kit comprising Compound (I) and a taxane, optionally with instructions for use.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: August 2, 2016
    Assignee: AstraZeneca AB
    Inventor: Barry Robert Davies
  • Patent number: 9320760
    Abstract: The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in time of survival in cancer patients, wherein the cancer either: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: April 26, 2016
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventor: Frederick H. Hausheer
  • Patent number: 9316632
    Abstract: Methods for selecting chemotherapeutic agents for treating a cancer are provided that include the steps of providing a cancer cell sample having a population of bulk cancer cells and a population of cancer stem-like cells, culturing a first portion of the cancer cell sample in a hydrodynamic focusing bioreactor under microgravity conditions and for a period of time to selectively enhance the population of cancer stem-like cells and selectively kill the population of bulk cancer cells, contacting the cancer stem-like cells with one or more chemotherapeutic agents, and then selecting the one or more chemotherapeutic agents for treating the cancer if there is an increase in an amount of cytotoxicity. Methods for treating a cancer are also provided in which the identified chemotherapeutic agents are administered to a subject. Further provided are methods for identifying a test compound useful for treating a cancer.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: April 19, 2016
    Assignee: MARSHALL UNIVERSITY RESEARCH CORPORATION
    Inventors: Pier Paolo Claudio, Jagan Valluri
  • Patent number: 9186410
    Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: November 17, 2015
    Assignees: The University of British Columbia, Centre for Drug Research and Development
    Inventors: Helen Burt, Donald Brooks, Jayachandran Kizhakkedathu, Richard Liggins, Dechi Guan, Lu Ye, Clement Mugabe, Alan So, Martin E. Gleave, John K. Jackson, Rajesh Kumar Kainthan
  • Patent number: 9180091
    Abstract: According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: November 10, 2015
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Julia M. Amadio, Peter H. R. Persicaner, Neda Irani, Janice Louise Cacace, Thorsteinn Thorsteinsson, Frederick D. Sancilio
  • Patent number: 9066918
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: June 30, 2015
    Assignee: Del Mar Pharmaceuticals
    Inventor: Dennis M. Brown